Gordon S M, Horsburgh C R, Peloquin C A, Havlik J A, Metchock B, Heifets L, McGowan J E, Thompson S E
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
J Infect Dis. 1993 Dec;168(6):1559-62. doi: 10.1093/infdis/168.6.1559.
Twenty-seven human immunodeficiency virus-infected patients with disseminated Mycobacterium avium complex disease who were treated with oral antimycobacterial agents (clofazimine, ciprofloxacin, ethambutol, and rifampin) were studied to evaluate the usefulness of monitoring serum drug concentrations and testing in vitro susceptibility of M. avium complex (MAC) isolates. Twenty patients tolerated treatment with three or four antimycobacterial agents for at least 8 weeks; mycobacteremia was eradicated in 7 (35%). The in vitro susceptibilities of MAC isolates to antimycobacterial agents were similar for these 7 and for the 13 who did not respond to antimycobacterial treatment. Serum drug levels were below the expected range in 6 of the 7 whose mycobacteremia was cleared and in 9 of the 13 nonresponders (P = .41). These low serum concentrations of antimycobacterial drugs may be due to impaired drug absorption in patients with AIDS and disseminated MAC disease.
对27例接受口服抗分枝杆菌药物（氯法齐明、环丙沙星、乙胺丁醇和利福平）治疗的播散性鸟分枝杆菌复合群病的人类免疫缺陷病毒感染患者进行了研究，以评估监测血清药物浓度和检测鸟分枝杆菌复合群（MAC）分离株体外药敏的有用性。20例患者耐受三或四种抗分枝杆菌药物治疗至少8周；7例（35%）的分枝杆菌血症得到根除。这7例患者以及13例对抗分枝杆菌治疗无反应患者的MAC分离株对抗分枝杆菌药物的体外药敏相似。在分枝杆菌血症得到清除的7例患者中有6例以及13例无反应者中有9例的血清药物水平低于预期范围（P = 0.41）。抗分枝杆菌药物的这些低血清浓度可能是由于艾滋病和播散性MAC病患者的药物吸收受损所致。
